Evolus

98 articles about Evolus

• Evolus Reports Second Quarter 2021 Results and Provides Business Update

  8/4/2021

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

• Evolus to Report Second Quarter 2021 Results and Provide Business Update

  7/22/2021

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2021 financial results and provide a business update on Wednesday, August 4, 2021, after the close of the U.S. financial markets.

• Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations

  6/30/2021

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program.

• Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color

  6/24/2021

  Evolus, Inc. announced a peer reviewed journal article was published in Dermatologic Surgery highlighting the efficacy and safety of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines, also known as frown lines between the eyes, in adult patients with Skin of Color.

• Evolus Appoints Dan Stewart as Vice President and General Manager, International

  5/19/2021

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the appointment of Dan Stewart as Vice President and General Manager of the company’s International business.

• Evolus Reports First Quarter 2021 Results and Provides Business Update

  5/12/2021

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today provided a business update and reported financial results for the first quarter 2021.

• Aesthetic Surgery Journal Publishes Long Term Safety and Efficacy Data of Jeuveau® for the Treatment of Moderate to Severe Frown Lines

  5/12/2021

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumtoxinA to decrease the appearance of glabellar lines, also known as frown lines between the eyes.

• Evolus to Report First Quarter 2021 Results and Provide Business Update

  5/4/2021

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that it will report its first quarter 2021 financial results and provide a business update on Wednesday, May 12, 2021, after the close of the U.S. financial markets.

• Evolus to Participate in the 7th Annual Truist Securities Life Sciences Summit

  4/29/2021

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that members of management will be participating in the 7th Annual Truist Securities Life Sciences Summit.

• Evolus Announces Pricing of Public Offering of Common Stock - Apr 22, 2021

  4/22/2021

  Evolus, Inc. announced the pricing of its public offering of 9,000,000 shares of its common stock at a public offering price of $9.50 per share, before underwriting discounts and commissions.

• Evolus Announces Proposed Public Offering of Common Stock - Apr 21, 2021

  4/21/2021

  Evolus, Inc. announced that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

• Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update

  3/24/2021

  Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau ® Pro Forma Cash Position of $57 Million at December 31, 2020 1

• Evolus to Report Fourth Quarter and Year End 2020 Results and Provide Business Update

  3/23/2021

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and year end 2020 financial results and provide a business update conference call and live audio webcast on Wednesday, March 24, 2021.

• Evolus Strengthens Balance Sheet Through a $25.5 Million Cash Infusion and Elimination of $127.4 Million of Debt and Milestone Payments

  3/23/2021

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced several transactions entered into with its strategic partner Daewoong Pharmaceutical Co. Ltd. (“Daewoong”) which further strengthen the Company’s balance sheet and financial position

• Evolus to Participate in Two Upcoming Investor Conferences - Mar 02, 2021

  3/2/2021

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that members of management will be participating in two upcoming virtual investor conferences.

• Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer

  2/26/2021

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of Crystal Muilenburg from VP, Corporate Communications & PR to Chief Marketing Officer effective today.

• Evolus Announces Preliminary, Unaudited, Fourth Quarter and Full Year 2020 Net RevenueQ4 2020 Net Revenue of $20.6 Million Increased 16% Over Q3 2020

  2/23/2021

  Evolus, Inc. announced its preliminary, unaudited, net revenues for the fourth quarter and full year ended December 31, 2020.

• Evolus to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

  2/19/2021

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference.

• Evolus Reports Third Quarter 2020 Results and Provides Business Update

  10/29/2020

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, reported financial results for the third quarter ended September 30, 2020 and provided a business update.

• Evolus Announces Promotion of Michael Mazen Jafar to Chief Commercial Officer and Jeff Plumer to General Counsel

  10/29/2020

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of two members of its Leadership Team.